iBreastExam™ (or iBE) is a game-changing technological breakthrough for countries and regions with rising incidence of breast cancer, most cases presenting at late stages and limited to no access to early detection for most women. iBreastExam™ harnesses the power of innovative sensor technology, software computing and mobile revolution, such that a doctor or any health-worker can offer objective and effective breast examinations, with ease and comfort.
The test is painless and radiation free, and takes less than 5 minutes to complete. The device can be used by any doctor or health worker and the results are available at the point-of-care. iBreastExam assesses differences in tissue elasticity between malignant and non-cancerous breast tissue, and its tactile sensor measures shear stiffness and tissue compression when applied to the skin.
iBE™ was originally invented at Drexel University in Philadelphia, PA. iBE™’s sensor technology accurately assesses & identifies tissue elasticity differences between hard & stiff breast cancer tumors versus normal, benign breast tissue. The patented tactile sensor technology using Piezoelectric Sensor Array, invented by the scientists and doctors at Drexel University is a novel, quantitative and low-cost elastic modulus (E) and shear modulus (G) sensor that can measure tissue compression and shear stiffness either by top down or lateral touching of the skin surface. iBE™’s ability to apply a force and measure the displacement electrically, all within the sensor, makes for an ideal ‘electronic palpation’ sensor for in-vivo breast imaging.
A major clinical study evaluating iBE™ technology was recently published in the Indian Journal of Gynecologic Oncology in June 2016. The study showed that iBreastExam device can significantly enhance clinical breast examination sensitivity (by 19%) while maintaining high specificity and Negative Predictive Value (NPV). The study concluded that iBreastExam can be a promising tool for early detection of clinically relevant lesions at early stages and also useful in younger women with dense breasts.
iBreastExam received FDA 510k clearance as a “Breast Lesion Documentation System”.
Comments are closed.